Nonclinical research CRO Citoxlab taps Christophe Berthoux as CEO for Europe

French flag
Berthoux is a CRO industry veteran, most recently as chief executive of Synexus. (nathanh100 / CC BY 2.0)

Citoxlab, a CRO for nonclinical research, has tapped Christophe Berthoux as chief executive for its European operations.

Berthoux has spent more than a quarter-century in the CRO industry, most recently as chief executive of U.K.-based clinical SMO Synexus. Previously, Berthoux held a number of positions at Charles River Laboratories.

“Following the recent acquisition of Solvo, Citoxlab now has six research centers in Europe (France, Hungary and Denmark),” Dr. Jean-François Le Bigot, president and CEO of Citoxlab group, said in a statement. “In this context, it became clear that we needed to reinforce our management structure.”


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Citoxlab picked up Hungary-based Solvo in March for an undisclosed price. With Solvo, which works in the expanding area of investigating the transport mechanisms pivotal in drug development, Citoxlab got 100 staffers and a new offering in the form of drug transporter studies and the assessment of Drug-Drug Interactions.

“At this time there are a lot of changes in pharma and biotech R&D,” Berthoux said in a statement. “As a scientifically driven CRO, I am convinced that Citoxlab has a lot of opportunities for future growth.”